Good morning, you're listening to Markets Desk.
Oil markets are commanding attention today as Brent crude has topped one hundred one dollars per barrel for the first time since July, driven by escalating conflict involving Iran. Diesel prices have surged to record highs, and analysts are warning that fuel shortages and inflationary pressure are no longer tail risks — they are arriving at the door.
Shifting to commodities with a longer horizon, copper is surfing all-time highs and the structural case remains intact. Electrification demand, grid buildout, and the energy transition are absorbing supply faster than miners can respond. One listed producer executive acknowledged the bear case — an AI spending pullback, a tariff reversal, or easing geopolitical tension — but argued the decade-long demand story holds regardless of near-term noise.
And in pharmaceuticals, Roche received FDA priority review for Enspryng, its treatment for myelin oligodendrocyte glycoprotein antibody-associated disease, a rare and debilitating neurological condition. Priority review designation shortens the FDA's evaluation window to six months, signaling the agency sees meaningful potential here. It is a meaningful regulatory milestone for Roche's neurology pipeline.
That's the tape. Markets Desk, signing off the floor.
